Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock

Key Points

• CFO Christopher Ryan Sullivan sold shares: he disposed of 7,979 shares on April 1 at an average $16.77 ($133,807.83) and 7,980 shares on April 2 at $17.15 ($136,857), executed under a pre‑arranged Rule 10b5‑1 plan and disclosed on an SEC Form 4, reducing his stake to 25,318 shares (a ~23.96% decrease).
• Company outlook and stock metrics: AVTX traded around $17.76 (12‑month range $3.39–$20.72) with a market cap near $405M; analysts show a consensus Moderate Buy with an average price target of $42.25, and the company recently reported an EPS beat (‑$0.37 vs. ‑$1.54 estimate).

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 7,979 shares of the company's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $16.77, for a total transaction of $133,807.83. Following the sale, the chief financial officer owned 25,318 shares of the company's stock, valued at $424,582.86. This trade represents a 23.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The stock was sold at an average price of $17.15, for a total value of $136,857.00.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock remained flat at $17.76 during trading on Friday. The stock had a trading volume of 1,109,141 shares, compared to its average volume of 845,897. Avalo Therapeutics, Inc. has a twelve month low of $3.39 and a twelve month high of $20.72. The company has a market cap of $404.75 million, a price-to-earnings ratio of -3.10 and a beta of 0.93. The stock has a 50 day moving average price of $15.50 and a two-hundred day moving average price of $15.91.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of ($0.21) million. On average, equities research analysts anticipate that Avalo Therapeutics, Inc. will post -19.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AVTX has been the topic of several analyst reports. Wall Street Zen raised shares of Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a report on Sunday, March 29th. Mizuho raised shares of Avalo Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Guggenheim began coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a "buy" rating and a $50.00 target price on the stock. Finally, HC Wainwright increased their price target on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $42.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Velan Capital Investment Management LP grew its holdings in Avalo Therapeutics by 38.4% during the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company's stock worth $773,000 after acquiring an additional 43,000 shares during the last quarter. Patient Square Capital LP bought a new position in shares of Avalo Therapeutics in the third quarter worth about $1,271,000. Cantor Fitzgerald L. P. acquired a new position in shares of Avalo Therapeutics during the third quarter worth approximately $1,083,000. Boothbay Fund Management LLC lifted its position in shares of Avalo Therapeutics by 1,916.6% during the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company's stock worth $2,902,000 after purchasing an additional 216,976 shares in the last quarter. Finally, Ally Bridge Group NY LLC bought a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $2,264,000. Institutional investors and hedge funds own 87.06% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.